4.7 Editorial Material

Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor

Related references

Note: Only part of the references are listed.
Review Pharmacology & Pharmacy

SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison

Fawaz F. Alqahtani

Summary: The paper discusses the key historical elements in the development of nuclear medicine imaging, focusing on Anger camera and SPECT technologies. It emphasizes the physics of detection in Anger camera systems and the components that affect image quality. The increasing use of SPECT/CT imaging and the integration of PET/CT systems are described, along with the correction methods for absorption within tissue. The article also compares SPECT/CT and PET/CT imaging systems, highlighting the higher photon detection and improved image resolution of PET/CT technology.

SAUDI PHARMACEUTICAL JOURNAL (2023)

Article Pharmacology & Pharmacy

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Doroteja Novak et al.

Summary: The broad availability and cost-effectiveness of Mo-99/Tc-99m generators worldwide have supported the use and development of novel Tc-99m-labelled radiopharmaceuticals. This study aimed to provide a reliable method for the facile preparation of a Tc-99m-labelled SST2 antagonist, [Tc-99m]Tc-TECANT-1, in a hospital radiopharmacy setting for a multi-centre clinical trial. A freeze-dried three-vial kit was successfully developed to ensure successful and reproducible on-site preparation of the radiopharmaceutical for human use shortly before administration.

PHARMACEUTICS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Somatostatin Receptor Antagonists for Imaging and Therapy

Melpomeni Fani et al.

JOURNAL OF NUCLEAR MEDICINE (2017)